Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics plc - American Depositary Shares
(NQ:
AUTL
)
1.990
+0.020 (+1.02%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Autolus Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
December 08, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
December 08, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
December 01, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK
↗
November 25, 2025
NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said.
Via
Stocktwits
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
November 25, 2025
AUCATZYL® will be available through routine commissioning by the UK National Health Service (NHS)
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
November 13, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
November 12, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
A Look at Autolus Therapeutics's Upcoming Earnings Report
↗
November 11, 2025
Via
Benzinga
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
November 03, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
October 30, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
October 27, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
October 20, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 15, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
September 16, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Intellectual Property
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
August 12, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
July 24, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
July 21, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
↗
June 30, 2025
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
Via
Benzinga
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
June 24, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END
Via
FinancialNewsMedia
What 4 Analyst Ratings Have To Say About Autolus Therapeutics
↗
June 12, 2025
Via
Benzinga
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
June 12, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Participate in Upcoming Investor Conferences
May 29, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens
↗
May 23, 2025
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia.
Via
Stocktwits
Topics
Artificial Intelligence
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
May 23, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
May 14, 2025
From
Autolus Therapeutics plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
